Buccal Drug Delivery System Market Share, Size, Trends, Industry Analysis Report, By Type (Sublingual Films, Buccal Tablets, Lozenges, Oral Sprays); By Application (Pain Management, Smoking Cessation, Angina Pectoris, Others); By End-Use (Hospitals, Ambulatory Centers, Others), By Region; Segment Forecast, 2022 - 2030
- Published Date:Feb-2022
- Pages: 118
- Format: PDF
- Report ID: PM2262
- Base Year: 2021
- Historical Data: 2018 - 2020
Report Outlook
The global buccal drug delivery system market was valued at USD 2.86 billion in 2021 and is expected to grow at a CAGR of 9.6% during the forecast period. The global market is primarily driven by factors such as ease of increasing use of smaller molecules, drug administration and termination, availability of blood vessels, low "first-pace effect," rapid absorption of drugs into plasma, rise in preference for macromolecules such as peptides, absorption enhancers, and other similar molecules, and growing availability of non-ionized drugs.
Know more about this report: request for sample pages
Additionally, the presence of prominent competitors in the medication distribution system industry and the availability of pharmaceuticals are expected to propel the global medication delivery system industry forward throughout the forecast period. However, the industry is expected to face hurdles in the anticipated period due to strict regulatory constraints and laws governing intellectual property rights. Nonetheless, the global industry is predicted to grow due to technical advancements and increased mergers and acquisitions over the forecast period.
Know more about this report: request for sample pages
Industry Dynamics
Growth Drivers
With this industry's continuous research and development, buccal medication delivery systems offer substantial growth potential. A buccal delivery system is regarded as the most convenient and favored option, especially among older patients, compared to oral dosing forms. This drug distribution system method eliminates first-pass metabolism, enabling the effective administration of pH-sensitive and readily destroyed medicines.
Quicker absorption, fewer side effects, less biofluid interaction, high concentration availability at the target site, and a shorter treatment regimen are some of the considerations driving the preference for buccal medication distribution. The key drivers for the buccal medication delivery system industry include a growing preference for self-administration of pharmaceuticals, increased advancements in injectable drug delivery systems, a high adoption rate of new healthcare technologies, and the high prevalence of chronic diseases.
Adopting sedentary lifestyles and irregularity in normal healthcare visits in emerging and developed countries has increased lifestyle-related chronic illnesses such as obesity, heart disorder, and diabetes. As a result, the need for buccal drug administration has increased as the number of cases of chronic disease has increased across the globe. Furthermore, the adoption of cutting-edge technologies in the healthcare industry will create further prospects for the buccal drug delivery system market to expand in the future years. Additionally, a surge in the preference for buccal medication delivery over traditional drug delivery methods is expected to boost the growth of the global buccal drug delivery system market.
Report Segmentation
The market is primarily segmented based on type, application, end-use, and region.
|
By Type |
By Application |
By End-Use |
By Region |
|
|
|
|
Know more about this report: request for sample pages
Insight by Product Type
In 2021, the buccal tablets and lozenges sector accounted for about XX% of the buccal drug delivery system industry. Consumer acceptance, cost-effectiveness, ease of formulation, and the large availability of medication candidates for formulation drive the segment's expansion. The sublingual films segment is expected to increase at the fastest rate during the projected period. The segment's rapid growth can be attributed to factors such as the quick availability of large concentrations of medication at a target site and greater research into developing controlled release formulations. These formulations are widely employed in anti-addiction treatments and emergency care centers due to their faster action start.
Insight by Application
In 2021, the smoking cessation segment had the highest share of almost XX%. When it comes to treating people addicted to nicotine or smoking, a buccal medication delivery system is frequently the most desired and effective method. Nicotine lozenges are more effective at delivering a more significant concentration of the medication than gums or other dosage forms. It's also a terrific option for individuals who don't want to constantly chew on their gums, as well as a great way to quit low and high-dependency smoking. Increased research and implementation of urgent treatment options such as sublingual pills, films, and injections have enhanced the acceptance of sublingual tablets, films, and injections outside hospitals, thereby boosting the angina pectoris segment.
Geographic Overview
North America dominates the drug distribution system market because of the developed pharmaceutical sector. Furthermore, throughout the projection period, the disease diagnosis and treatment rate will accelerate the expansion of the drug distribution system market growth in the region.
The presence of a large number of market players, enhanced research to identify suitable drug candidates, significant investment by prominent players to improve the development of innovative formulations, and improved diagnosis and treatment rates are all factors driving regional market expansion. High adoption rates and advantageous reimbursement scenarios are two aspects that are likely to drive regional market expansion.
Due to the advancement of the pharmaceutical industry, Asia Pacific is expected to see considerable growth in the market. A rise in the senior population, the pharmaceutical industry's development, and a massive increase in domestic players are all expected to enhance the regional market growth. The region has the highest proportion of the senior population, which is vulnerable to various lifestyle-related cardiovascular diseases. The regional market is driven by rising awareness of de-addiction treatments and the easy availability of OTC products.
Competitive Insight
Applied Pharma Research, ARDEA BIOSCIENCES LIMITED, ARx LLC, AstraZeneca, Bayer AG, BioDelivery Sciences International, Inc., Catalent, Cynapsus Therapeutics Inc., Dr. Reddy's Laboratories Ltd, Endo Pharmaceuticals plc, F. Hoffmann-La Roche Ltd, Generex Biotechnology, GlaxoSmithKline plc, Indivior PLC, MedLab, NAPP PHARMACEUTICALS LIMITED, Novartis AG, Novo Nordisk A/S, Pfizer Inc., Sanofi, Takeda Pharmaceutical Company Limited., and Teva Pharmaceutical Industries Ltd are some of the major players in the buccal drug delivery system market.
Buccal Drug Delivery System Market Report Scope
|
Report Attributes |
Details |
|
Market size value in 2021 |
USD 2.86 billion |
|
Revenue forecast in 2030 |
USD 6.31 billion |
|
CAGR |
9.6% from 2022 - 2030 |
|
Base year |
2021 |
|
Historical data |
2018 - 2020 |
|
Forecast period |
2022 - 2030 |
|
Quantitative units |
Revenue in USD million/billion and CAGR from 2022 to 2030 |
|
Segments covered |
By Type, By Application, By End-Use, By Region |
|
Regional scope |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
|
Key Companies |
Applied Pharma Research, ARDEA BIOSCIENCES LIMITED, ARx LLC, AstraZeneca, Bayer AG, BioDelivery Sciences International, Inc., Catalent, Cynapsus Therapeutics Inc., Dr. Reddy’s Laboratories Ltd, Endo Pharmaceuticals plc, F. Hoffmann-La Roche Ltd, Generex Biotechnology, GlaxoSmithKline plc, Indivior PLC, MedLab, NAPP PHARMACEUTICALS LIMITED, Novartis AG, Novo Nordisk A/S, Pfizer Inc., Sanofi, Takeda Pharmaceutical Company Limited., and Teva Pharmaceutical Industries Ltd |
© 2024 Polaris Market Research and Consulting. All rights reserved
